CD8A and neoplasm: Haojun Chen et al. discovered in MC38 bearing C57BL/6 mice, 177Lu-EB-RGD (18.5 MBq) combined with anti-PD-L1 antibody (10 mg/kg) synergistically enhances anti-tumor immunity by stimulating CD8+ T cell infiltration, improving tumor control, overall survival and protecting against tumor rechallenge.